<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892448</url>
  </required_header>
  <id_info>
    <org_study_id>20150281</org_study_id>
    <nct_id>NCT02892448</nct_id>
  </id_info>
  <brief_title>Cardiac MRI for Metal on Metal Hip Resurfacing</brief_title>
  <acronym>CardiacMRI</acronym>
  <official_title>Cardiac MRI for Metal on Metal Orthopaedic Prostheses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There may be a relationship between heart function and the metal ion levels in patients&#xD;
      having undergone total hip replacement. The idea is to use results from a clinical cardiac&#xD;
      MRI to assess heart function in a sample of 30 patients whom have undergone either&#xD;
      metal-on-metal hip replacement (unilateral or bilateral) or a non-metal on metal total hip&#xD;
      replacement to determine whether having undergone a metal on metal hip procedure may be&#xD;
      impacting heart function. In addition to the clinically used parameters, the images will also&#xD;
      be retrospectively assessed using special software to assess amount of fibrosis and early&#xD;
      changes affecting cardiac muscle contraction which may be indicative of impaired heart&#xD;
      function. With these values we will compare to known, and previously collected, hip&#xD;
      replacement and function data to determine whether there is any differences in how the heart&#xD;
      works in those having had a hip replacement relative to a normal population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There has been some recent concern regarding possible systemic health effects resulting from&#xD;
      elevated blood cobalt concentrations in patients with cobalt containing hip implants (1). To&#xD;
      date there are no blood cobalt criteria to help guide physicians when evaluating an&#xD;
      individual hip implant patient's risk of developing systemic health effects because&#xD;
      historically there was little or no concern about systemic cobalt toxicity in implant&#xD;
      patients. Included within this is heart function, for which investigators see a need to use&#xD;
      this novel software to analyze heart function relative to Hip status and Metal Ion levels.&#xD;
&#xD;
      Patients with metal on metal hip prosthesis are subject to local and systemic release of&#xD;
      cobalt and chromium ions which may increase the potential for locally aggressive ion-induced&#xD;
      local tissue reactions such as pseudotumours, a type of Adverse Reaction to Metal Debris&#xD;
      (ARMD) (2). Although there have been reports of local toxicity as well as cases of cobaltism&#xD;
      (as seen during outbreak in Quebec of so called 'cobalt beer drinkers' cardiomyopathy)&#xD;
      leading to cardiac and ototoxicity, it is unclear if chronic exposure to these ions can lead&#xD;
      to impaired cardiac function (cardiotoxicity) in a well-functioning prosthesis.&#xD;
&#xD;
      The majority of the blood cobalt concentrations reported for hip implant patients appear to&#xD;
      range from approximately 0.2 to 10 Âµg/L, and based on our review of the available literature,&#xD;
      should not pose an increased risk for the development of systemic health effects.&#xD;
&#xD;
      The concern for systemic health effects is for the small number of patients with&#xD;
      cobalt-containing hip implants with markedly elevated blood cobalt concentrations.&#xD;
&#xD;
      Extensive evaluations of these 'cobalt beer drinkers' have found that poor nutrition and&#xD;
      underlying disease states caused by severe alcoholism were likely significant contributing&#xD;
      factors to heart disease in this particular population. However, there remains a significant&#xD;
      concern that cardiac function could be affected in the long term. This is especially relevant&#xD;
      as the majority of these implants are put in patients less than 50 years age.&#xD;
&#xD;
      Cardiac magnetic resonance imaging (CMR) is the gold standard method to assess cardiac&#xD;
      function in patients at risk of cardiotoxicity. In addition to assessing cardiac function,&#xD;
      CMR enables imaging of inflammation, and fibrosis (which may be secondary to the ion&#xD;
      deposition) in the heart which may provide more specific information about the mechanism of&#xD;
      injury in these patients.&#xD;
&#xD;
      The purpose of this study is to look at cardiac function in patients with a metal on metal&#xD;
      hip prostheses.&#xD;
&#xD;
      Recruitment: 30 patients in total (10 unilateral and 10 bilateral hip resurfacing patients&#xD;
      and 10 non-metal on metal total hip replacement patients) will be recruited which should&#xD;
      provide indication of relationship both between either instances and heart function, as well&#xD;
      as compared to one another. All patients will be undergoing clinical cardiac MRI. All&#xD;
      patients will have extra images collected during their MRI and these images will be analyzed&#xD;
      to determine any relationship between heart function and the possible metal ion levels from&#xD;
      the hip implant. As part of the scan analysis they will be required to also have a 5&#xD;
      millilitres (mLs) vial of blood collected. Ultrasound values will be retrospectively&#xD;
      collected, for analysis of soft tissue reaction, from a previous clinically ordered&#xD;
      ultrasound of the affected joint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">July 20, 2019</completion_date>
  <primary_completion_date type="Actual">July 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Ejection Fraction</measure>
    <time_frame>Minimum 5 years post-operative</time_frame>
    <description>The volumetric fraction of fluid ejected from a chamber with each contraction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehensive Cardiac Function</measure>
    <time_frame>One time measure at CMR</time_frame>
    <description>Volume measures including: left ventricular end-diastolic volume, left ventricular stroke volume, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular stroke volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T2* Mapping Time</measure>
    <time_frame>One time measure at CMR</time_frame>
    <description>T2* is a specific sequence in the cardiac MRI and mapping can lead to important indicators of cardiac structure and function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1 Mapping Time</measure>
    <time_frame>One time measure at CMR</time_frame>
    <description>T1 is a specific sequence in the cardiac MRI and mapping can lead to important indicators of cardiac structure and function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cobalt and Chromium Ion Levels</measure>
    <time_frame>Immediately Prior to cardiac MRI</time_frame>
    <description>To measure the level of cobalt and chromium ions in blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Unilateral Hip Resurfacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilateral Hip Resurfacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Metal on Metal Total Hip</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging (CMR)</intervention_name>
    <description>Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
    <arm_group_label>Bilateral Hip Resurfacing</arm_group_label>
    <arm_group_label>Non-Metal on Metal Total Hip</arm_group_label>
    <arm_group_label>Unilateral Hip Resurfacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing clinical Cardiac MRI&#xD;
&#xD;
          -  Currently enrolled with either unilateral or bilateral metal-on-metal (MoM) Hip&#xD;
             replacement device&#xD;
&#xD;
          -  Willing to sign Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient does not meet all 'inclusion' criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E Beaule, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paul E Beaule</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Kim PR, BeaulÃ© PE, Dunbar M, Lee JK, Birkett N, Turner MC, Yenugadhati N, Armstrong V, Krewski D. Cobalt and chromium levels in blood and urine following hip resurfacing arthroplasty with the Conserve Plus implant. J Bone Joint Surg Am. 2011 May;93 Suppl 2:107-17. doi: 10.2106/JBJS.J.01721.</citation>
    <PMID>21543699</PMID>
  </reference>
  <reference>
    <citation>Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB; Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013 Oct 14;15:92. doi: 10.1186/1532-429X-15-92. Review.</citation>
    <PMID>24124732</PMID>
  </reference>
  <reference>
    <citation>Messroghli DR, Greiser A, FrÃ¶hlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging. 2007 Oct;26(4):1081-6.</citation>
    <PMID>17896383</PMID>
  </reference>
  <reference>
    <citation>Diesbourg LD, Prato FS, Wisenberg G, Drost DJ, Marshall TP, Carroll SE, O'Neill B. Quantification of myocardial blood flow and extracellular volumes using a bolus injection of Gd-DTPA: kinetic modeling in canine ischemic disease. Magn Reson Med. 1992 Feb;23(2):239-53.</citation>
    <PMID>1549039</PMID>
  </reference>
  <results_reference>
    <citation>Juneau D, Grammatopoulos G, Alzahrani A, Thornhill R, Inacio JR, Dick A, Vogel KI, Dobransky J, BeaulÃ© PE, Dwivedi G. Is end-organ surveillance necessary in patients with well-functioning metal-on-metal hip resurfacings? A cardiac MRI survey. Bone Joint J. 2019 May;101-B(5):540-546. doi: 10.1302/0301-620X.101B5.BJJ-2018-1478.R1.</citation>
    <PMID>31039002</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <results_first_submitted>April 24, 2020</results_first_submitted>
  <results_first_submitted_qc>July 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02892448/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Unilateral Hip Resurfacing</title>
          <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
        <group group_id="P2">
          <title>Bilateral Hip Resurfacing</title>
          <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
        <group group_id="P3">
          <title>Non-Metal on Metal Total Hip</title>
          <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screening failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Unilateral Hip Resurfacing</title>
          <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
        <group group_id="B2">
          <title>Bilateral Hip Resurfacing</title>
          <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
        <group group_id="B3">
          <title>Non-Metal on Metal Total Hip</title>
          <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" lower_limit="52.2" upper_limit="66.5"/>
                    <measurement group_id="B2" value="57.7" lower_limit="48.5" upper_limit="70.1"/>
                    <measurement group_id="B3" value="58.4" lower_limit="51.8" upper_limit="70.2"/>
                    <measurement group_id="B4" value="58.5" lower_limit="48.5" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since implantation</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1" lower_limit="5.9" upper_limit="11.1"/>
                    <measurement group_id="B2" value="7.5" lower_limit="6.7" upper_limit="9.1"/>
                    <measurement group_id="B3" value="6.7" lower_limit="5.0" upper_limit="10.6"/>
                    <measurement group_id="B4" value="7.8" lower_limit="5.0" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" lower_limit="25.1" upper_limit="31.1"/>
                    <measurement group_id="B2" value="29.0" lower_limit="25.3" upper_limit="34.4"/>
                    <measurement group_id="B3" value="27.1" lower_limit="22.5" upper_limit="32.5"/>
                    <measurement group_id="B4" value="28.1" lower_limit="22.5" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (BSA)</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.04" lower_limit="1.93" upper_limit="2.23"/>
                    <measurement group_id="B2" value="2.08" lower_limit="1.79" upper_limit="2.32"/>
                    <measurement group_id="B3" value="1.97" lower_limit="1.69" upper_limit="2.45"/>
                    <measurement group_id="B4" value="2.03" lower_limit="1.69" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Ejection Fraction</title>
        <description>The volumetric fraction of fluid ejected from a chamber with each contraction.</description>
        <time_frame>Minimum 5 years post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unilateral Hip Resurfacing</title>
            <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O2">
            <title>Bilateral Hip Resurfacing</title>
            <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O3">
            <title>Non-Metal on Metal Total Hip</title>
            <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Ejection Fraction</title>
          <description>The volumetric fraction of fluid ejected from a chamber with each contraction.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left ventricular ejection fraction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="60" upper_limit="69"/>
                    <measurement group_id="O2" value="66" lower_limit="63" upper_limit="72"/>
                    <measurement group_id="O3" value="65" lower_limit="59" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ventricular ejecton fraction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="60" upper_limit="64"/>
                    <measurement group_id="O2" value="63" lower_limit="58" upper_limit="70"/>
                    <measurement group_id="O3" value="62" lower_limit="60" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comprehensive Cardiac Function</title>
        <description>Volume measures including: left ventricular end-diastolic volume, left ventricular stroke volume, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular stroke volume</description>
        <time_frame>One time measure at CMR</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unilateral Hip Resurfacing</title>
            <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O2">
            <title>Bilateral Hip Resurfacing</title>
            <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O3">
            <title>Non-Metal on Metal Total Hip</title>
            <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
        </group_list>
        <measure>
          <title>Comprehensive Cardiac Function</title>
          <description>Volume measures including: left ventricular end-diastolic volume, left ventricular stroke volume, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular stroke volume</description>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left ventricle end-diastolic volume (LVEDV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="68" upper_limit="80"/>
                    <measurement group_id="O2" value="73" lower_limit="65" upper_limit="85"/>
                    <measurement group_id="O3" value="67" lower_limit="61" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left ventricle end-systolic volume (LVESV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="20" upper_limit="39"/>
                    <measurement group_id="O2" value="26" lower_limit="23" upper_limit="29"/>
                    <measurement group_id="O3" value="23" lower_limit="19" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left ventricle stroke volume (LVSV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="42" upper_limit="56"/>
                    <measurement group_id="O2" value="46" lower_limit="41" upper_limit="62"/>
                    <measurement group_id="O3" value="43" lower_limit="41" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ventricle end-diastolic volume (RVEDV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="76" upper_limit="87"/>
                    <measurement group_id="O2" value="82" lower_limit="76" upper_limit="84"/>
                    <measurement group_id="O3" value="71" lower_limit="64" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ventricle end-systolic volume (RVESV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="22" upper_limit="35"/>
                    <measurement group_id="O2" value="30" lower_limit="24" upper_limit="31"/>
                    <measurement group_id="O3" value="28" lower_limit="22" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ventricle stroke volume (RVSV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="46" upper_limit="57"/>
                    <measurement group_id="O2" value="50" lower_limit="41" upper_limit="56"/>
                    <measurement group_id="O3" value="43" lower_limit="41" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T2* Mapping Time</title>
        <description>T2* is a specific sequence in the cardiac MRI and mapping can lead to important indicators of cardiac structure and function.</description>
        <time_frame>One time measure at CMR</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unilateral Hip Resurfacing</title>
            <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O2">
            <title>Bilateral Hip Resurfacing</title>
            <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O3">
            <title>Non-Metal on Metal Total Hip</title>
            <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
        </group_list>
        <measure>
          <title>T2* Mapping Time</title>
          <description>T2* is a specific sequence in the cardiac MRI and mapping can lead to important indicators of cardiac structure and function.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myocardium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="32" upper_limit="34"/>
                    <measurement group_id="O2" value="33" lower_limit="32" upper_limit="34"/>
                    <measurement group_id="O3" value="33" lower_limit="30" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="23" upper_limit="29"/>
                    <measurement group_id="O2" value="24" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O3" value="28" lower_limit="27" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1 Mapping Time</title>
        <description>T1 is a specific sequence in the cardiac MRI and mapping can lead to important indicators of cardiac structure and function.</description>
        <time_frame>One time measure at CMR</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unilateral Hip Resurfacing</title>
            <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O2">
            <title>Bilateral Hip Resurfacing</title>
            <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O3">
            <title>Non-Metal on Metal Total Hip</title>
            <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
        </group_list>
        <measure>
          <title>T1 Mapping Time</title>
          <description>T1 is a specific sequence in the cardiac MRI and mapping can lead to important indicators of cardiac structure and function.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Native T1 left ventricle (LV) average</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1003" lower_limit="988" upper_limit="1014"/>
                    <measurement group_id="O2" value="988" lower_limit="980" upper_limit="997"/>
                    <measurement group_id="O3" value="993" lower_limit="987" upper_limit="1007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post gadolinium T1 left ventricle (LV) average</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402" lower_limit="384" upper_limit="432"/>
                    <measurement group_id="O2" value="409" lower_limit="402" upper_limit="418"/>
                    <measurement group_id="O3" value="383" lower_limit="371" upper_limit="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cobalt and Chromium Ion Levels</title>
        <description>To measure the level of cobalt and chromium ions in blood</description>
        <time_frame>Immediately Prior to cardiac MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unilateral Hip Resurfacing</title>
            <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O2">
            <title>Bilateral Hip Resurfacing</title>
            <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
          <group group_id="O3">
            <title>Non-Metal on Metal Total Hip</title>
            <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
          </group>
        </group_list>
        <measure>
          <title>Cobalt and Chromium Ion Levels</title>
          <description>To measure the level of cobalt and chromium ions in blood</description>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chromium blood levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="0.97" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.58" lower_limit="1.60" upper_limit="2.90"/>
                    <measurement group_id="O3" value="0.11" lower_limit="0.10" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cobat blood levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.50" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.47" lower_limit="1.33" upper_limit="2.16"/>
                    <measurement group_id="O3" value="0.18" lower_limit="0.16" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Unilateral Hip Resurfacing</title>
          <description>Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
        <group group_id="E2">
          <title>Bilateral Hip Resurfacing</title>
          <description>Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
        <group group_id="E3">
          <title>Non-Metal on Metal Total Hip</title>
          <description>Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).&#xD;
Cardiac magnetic resonance imaging (CMR): Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul E Beaule</name_or_title>
      <organization>The Ottawa Hospital Research Institute</organization>
      <phone>613-737-8899 ext 73265</phone>
      <email>pbeaule@toh.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

